1
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Condition(s):Ductal Breast Carcinoma In Situ; HER2/Neu PositiveLast Updated:April 20, 2018Completed
Breast Carcinoma In Situ: 518 Clinical Trials, Page 1 of 52
Hide Studies Not Open or Pending
2
Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ
Condition(s):Breast CancerLast Updated:May 17, 2017Completed
3
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
Condition(s):Ductal Breast Carcinoma in Situ; Estrogen Receptor-positive Breast CancerLast Updated:July 21, 2015Completed
4
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
Condition(s):Ductal Breast Carcinoma In SituLast Updated:October 26, 2020Active, not recruiting
5
Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer
Condition(s):Breast NeoplasmsLast Updated:March 17, 2015Recruiting
6
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
Condition(s):Atypical Ductal Breast Hyperplasia; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in SituLast Updated:September 7, 2020Recruiting
7
Phase II Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
Condition(s):Ductal Breast Carcinoma in SituLast Updated:February 6, 2020Recruiting
8
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Condition(s):Ductal Breast Carcinoma In SituLast Updated:October 22, 2020Active, not recruiting
9
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Condition(s):Ductal Breast Carcinoma In SituLast Updated:September 4, 2020Recruiting
10
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
Condition(s):Ductal Breast Carcinoma In SituLast Updated:August 5, 2020Active, not recruiting